BeyondSpring CEO says Plinabulin trial in NSCLC 'going forward really nicely'
BeyondSpring (BYSI) is a global biopharmaceutical company focused on the development of innovative cancer therapies. In an exclusive interview with The Fly, CEO Lan Huang discussed the ongoing Phase 3 trial of Plinabulin/docetaxel in refractory non-small cell lung cancer, or NSCLC: "The study is going forward really nicely. We have enrolled over 420 patients now globally, and we have already finished our first interim look. In the first interim look, the DSMB also reviewed our data not only on the safety but also on efficacy and there's no resizing of the patients. They advised us to go forward without upsizing the patient count. From a sophisticated investor point of view that data looks pretty good, trending in the right direction, and we are very happy with that. Regarding the second look, everything's going forward as we planned and we are expecting probably by the end of this year or next year, because it's all driven by events. We will also need to clean the data before we can say anything and that's why the timeline is not carved in stone. But as far as what we can see from our side, things are progressing nicely forward as we planned." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.